Upload
adele-malone
View
214
Download
0
Tags:
Embed Size (px)
Citation preview
Structural basis for the EBA-175 erythrocyte invasion pathway of themalaria parasite Plasmodium falciparum
Tolia NH, Enemark EJ, Sim KL, Joshua-Tor L Cell 122: 183-193, 2005
Structural basis for Duffy recognition by the malaria parasite Duffy-binding–like domain
Singh SK, Hora R, Belrhali H, Chitnis CE, Sharma A
Nature 439: 741-744, 2005
Critical Evaluation of Published Literature BMSD 542, Winter 2006
Background
Plasmodium causes Malaria which affects more than 500 million people and kills about two million annually.
P. falciparum is the most prevalent; P. vivax less so; P. knowlesi is the simian counterpart.
Infection is caused by sporozoites entering into the host bloodstream after a female Anopheles mosquito bite and infecting hepatocytes; the
hepatocytes rupture and release thousands of merozoites each of which can invade an erythrocyte, thus initiating the asexual erythrocytic stage
of the parasite’s life cycle.
All pathological and clinical manifestations of the disease are caused by this critical invasion step.
Background, continued…
Binding to the host endothelium is accomplished through the function of a common adhesion molecule found in two families of parasite ligands.
EBL (erythrocyte binding ligand) family of erythrocyte invasion ligands and the var/PfEMP1 (P. falciparum erythrocyte membrane protein 1)
family of cytoadherence ligands
This adhesive domain, called the Duffy-binding like (DBL) domain was first described as part of the Duffy Binding Protein (DBP), an important
invasion ligand of both P. vivax and P. knowlesi for erythrocytes.
DBL domains contribute to both invasion and cytoadherence and are one of the most versatile and polymorphic adhesive molecules.
X-ray crystallography structures of the DBL domains from two well-studied EBL ligands, the P. knowlesi DBP (PkDBP) and the P.
falciparum EBA-175, have been published.
EBP, EBA, PfEMP, …
Nature 439: 741-744, 2005
EBL, DBL, DBP, PfEMP, …
Cell 122: 183-193, 2005 erythrocyte binding domain (critical)
PkDBP alignments
Nature 439: 741-744, 2005
EBA-175 alignments
Cell 122: 183-193, 2005
PkDBP structure (3 Å)
11 alpha helices, unique fold, three subdomains
Nature 439: 741-744, 2005
EBA-175 structure (2.3 Å)
Cell 122: 183-193, 2005
Binding
DBL domains bind several substrates and have different binding sites, sometimes involving dimerisation.
EBA-175 and PkDBP bind different receptors on the erythrocyte surface.
PkDBL (and PvDBL) bind the host DARC (Duffy antigen receptor for chemokines); mutagenesis data available.
EBA-175, BAEBL, and JSEBL all can bind sialic acid residues, but each recognises different erythrocyte sialoglycoproteins; receptor for EBA-
175 is human RBC receptor glycophorin A. Redundant pathways means that EBA-175 is not essential.
X-ray structure of EBA-175 was solved with sialic acid derivative, alpha-2,3,sialyllactoase to identify the glycan binding site; additional
mutagenesis experiments were performed.
PkDBL binding
Nature 439: 741-744, 2005
PvDBL binding
Nature 439: 741-744, 2005
polymorphic residues in field isolates; immune systemevasion
binding site“just-in-time” releaseand binding to receptor
PkDBL binding
SD1
SD2
SD2DARC bindingsite antigenic
site
antigenicsite
EBA-175 binding
Cell 122: 183-193, 2005
Model for EBA-175 region 2 binding to glycophorin A
Cell 122: 183-193, 2005
Superimposed DBLs (within 2 Å of each other)
DARC bindingsite glycan
bindingsites
A treasure of insights
A treasure of insights
DARC bindingsite
glycan binding
site
Conclusions – insights from x-ray structures
Different sites target different substrates and receptors in different DBL domains
Interplay between sequence conservation and variation to evade immune evasion
For PvDBL, target the DBL-DARC interaction for therapeutics (conserved)
For EBA-175, target the glycan binding sites; distrupt dimersation and/or DBL domain interactions